{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T02:08:32Z","timestamp":1781402912987,"version":"3.54.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).<\/jats:p>","DOI":"10.3389\/fonc.2025.1740357","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:27:51Z","timestamp":1768458471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: FIA plus venetoclax in a patient on hemodialysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Jacob E.","family":"Herstein","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Health Science Center at Houston","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh R.","family":"Marx","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Savoy","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Ying","family":"Jen","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000167","article-title":"Management of patients with end-stage renal disease undergoing chemotherapy: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Societ\u00e0 Italiana di Nefrologia (SIN)","volume":"2","author":"Pedrazzoli","year":"2017","journal-title":"ESMO Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp598","article-title":"Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients","volume":"21","author":"Janus","year":"2010","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: New therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-635060","article-title":"How I treat acute myeloid leukemia presenting with preexisting comorbidities","volume":"128","author":"Ofran","year":"2016","journal-title":"Blood. Am Soc Hematology;"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.732","article-title":"Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report","volume":"4","author":"Akagi","year":"2023","journal-title":"EJHaem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1721727X1100900310","article-title":"Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis","volume":"9","author":"Kourelisi","year":"2011","journal-title":"Eur J Inflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116","article-title":"Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy","volume":"1","author":"Gandhi","year":"1993","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120005903","article-title":"The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: A prospective dose adjustment study","volume":"20","author":"Lichtman","year":"2002","journal-title":"Cancer Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","article-title":"International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency","volume":"43","author":"Lichtman","year":"2007","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1563","article-title":"The association between high-dose cytarabine neurotoxicity and renal insufficiency","volume":"7","author":"Damon","year":"1989","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.833","article-title":"High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency","volume":"15","author":"Smith","year":"1997","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0171-7","article-title":"AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity","volume":"88","author":"Lindner","year":"2008","journal-title":"Int J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1373-2","article-title":"Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure","volume":"67","author":"Radeski","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217754244","article-title":"Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report","volume":"25","author":"Ettleson","year":"2019","journal-title":"J Oncol Pharm Practice"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.11.004","article-title":"Salvage chemotherapy followed by autologous stem-cell transplantation using targeted busulfan for refractory diffuse large B-cell lymphoma with dialysis-dependent end-stage renal disease","volume":"20","author":"Morita","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.4.679","article-title":"Cytarabine and neurologic toxicity","volume":"9","author":"Baker","year":"1991","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1188\/15.CJON.270-272","article-title":"Implementation and evaluation of a high-dose cytarabine neurologic assessment tool","volume":"19","author":"Szoch","year":"2015","journal-title":"Clin J Oncol Nurs"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-415948-8.00015-5","article-title":"Pharmacokinetics of Anti-cancer Chemotherapy in Renal Insufficiency and Dialysis","volume-title":"Renal Disease in Cancer Patients","author":"Fissell","year":"2014"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A southeastern cancer study group study","volume":"10","author":"Vogler","year":"1992","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.901.901","article-title":"SWOG S1203: A randomized phase III study of standard cytarabine plus daunorubicin (7 + 3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML)","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1740357\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:56:10Z","timestamp":1771916170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1740357\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":21,"alternative-id":["10.3389\/fonc.2025.1740357"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1740357","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"1740357"}}